We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Index Ventures and Amunix Invest in Diartis Pharmaceuticals

News   Feb 17, 2011

 
Index Ventures and Amunix Invest in Diartis Pharmaceuticals
 
 
 

RELATED ARTICLES

Clinical Trial Assessing Treatments for Preventing People at High Risk From Developing Multidrug-resistant TB Launches

News

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.

READ MORE

Unearthing the Proteome of the Sweet Potato

News

The sweet, starchy orange sweet potatoes are tasty and nutritious ingredients for fries, casseroles and pies. Although humans have been cultivating sweet potatoes for thousands of years, scientists still don't know much about the protein makeup of these tubers, until now.

READ MORE

Sickle Cell Drug IMR-687 Shows Promise in Clinical Trial

News

An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE